No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

Alicia Gutierrez-Valencia1,*, Coral García2, Pompeyo Viciana1, Yusnelkis Milanés-Guisado1, Tamara Fernandez-Magdaleno1, Nuria Espinosa1, Juan Pasquau2, Luis Fernando López-Cortés1*

1 Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain,
2 Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen de las Nieves, Granada, Spain

* luisfernando@lopezctortes.net(LFLC); alicia.gutierrez.valencia@gmail.com(AGV)

Abstract

Background
Simplification strategies of antiretroviral treatment represent effective tools for the reduction of drug-induced toxicity, resistance mutations in case of virological failure and costs.

Objectives
To assess the effectiveness of simplification to atazanavir/ritonavir (ATVrtv) or unboosted atazanavir (ATV400) plus lamivudine, and if low plasma or intracellular ATV Ctrough influence virological outcomes.

Methods
Ambispective observational study in patients with undetectable HIV-RNA who were switched to ATVrtv or ATV400 plus lamivudine once daily. Previous virological failures (VF) were allowed if the resistance tests showed major resistance mutation neither to ATV nor to lamivudine. VF was defined as two consecutive plasma HIV-RNA >200 copies/mL. Effectiveness was assessed by intention-to-treat and on-treatment analyses. Plasma and intracellular ATV Ctrough were measured by LC-MS/MS.

Result
A total of 246 patients were included. At week 48, the Kaplan–Meier estimation of efficacy within the ATVrtv and ATV400 groups were 85.9% [95% confidence interval, (CI95), 80.3–91.4%] versus 87.6% (CI95, 80.1–94.1%) by intention-to-treat analysis (p = 0.684), and 97.7% (CI95, 95.2–100%) versus 98.8% (CI95, 97.0–100%) by on-treatment analysis (p = 0.546), respectively. Plasma and intracellular ATV Ctrough were significantly higher with ATVrtv than with ATV400 (geometric mean (GM), 318.3 vs. 605.9 ng/mL; p = 0.013) and (811.3 vs.
2659.2 ng/mL; \( p = 0.001 \), respectively. Only 14 patients had plasma \( C_{\text{trough}} \) below the suggested effective concentration for ATV (150 ng/mL). No relationship between plasma or intracellular \( C_{\text{trough}} \) and VF or blips were found.

**Conclusion**

Boosted or unboosted ATV plus lamivudine is effective and safe, and the lower plasma \( C_{\text{trough}} \) observed with ATV\(_{400}\) do not compromise the effectiveness of these simplification regimens in long-term virologically suppressed HIV-1-infected patients.

**Introduction**

The first attempts of simplifying antiretroviral treatment (ART) in virologically suppressed HIV-1-infected patients were less effective compared with maintaining triple-drug therapy, probably due to the low genetic barrier and/or antiviral potency of the drugs used at that time [1,2]. In recent years, the availability of new drugs with improved genetic barrier and potency, particularly ritonavir-boosted protease inhibitors (PI), have led to a re-emergence of simplification strategies. The key rationales for simplifying ART are the reduction of both drug-induced toxicities and the risk of resistance mutations in case of virological failure, as well as the cost [3–7]. Two randomized clinical trials have demonstrated non-inferiority of ATV\(_{\text{rtv}}\) plus lamivudine (3TC) compared with ATV\(_{\text{rtv}}\) plus two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-infected patients with virological suppression (VL) [8–10]. Based in their results, dual therapy including atazanavir 300 mg plus ritonavir 100 mg (ATV\(_{\text{rtv}}\)) plus 3TC might represents a good simplification strategy, as ATV has been associated with lower rates of lipid abnormalities than other PIs [11–13] and has a good resistance profile. However, ATV\(_{\text{rtv}}\) is not always well tolerated due to potential toxicity related both to high ATV plasma concentrations as well as to the use of ritonavir, including gastrointestinal disturbances, lipid profile alterations, and hyperbilirubinemia. Indeed, it has been observed that switching patients with virological suppression on ATV\(_{\text{rtv}}\) plus two NRTIs to 400 mg unboosted ATV once daily (ATV\(_{400}\)) improves toxicity and tolerability without loss of virological suppression [14–18]. However, dual therapy comprising ATV\(_{400}\) plus 3TC has been rarely explored, although some data suggest similar effectiveness as compared to ATV\(_{\text{rtv}}\) plus 3TC in patients on long-lasting virological suppression [19,20].

A minimum plasma trough concentration (concentration at the end of interval dosing; \( C_{\text{trough}} \)) of 150 ng/mL has been proposed for ATV to be effective when given with two NRTIs [21]. Since the pharmacokinetic variability of ritonavir-boosted ATV is high, it is not uncommon for patients to show an ATV plasma trough concentration (\( C_{\text{trough}} \)) below this recommended level. In the case of ATV\(_{400}\), the plasma concentrations are lower and show an even higher variability than with ATV\(_{\text{rtv}}\) [22–24]; however, it remains unknown whether this influences the effectiveness of the drug to a higher extent than with ATV\(_{\text{rtv}}\) when administered in dual therapy.

Therefore, the aim of this study was to determine the effectiveness of boosted and unboosted ATV plus 3TC in virologically suppressed HIV-1-infected patients, as well as to evaluate the relationship between plasma and intracellular ATV \( C_{\text{trough}} \) with the virological outcome.
Material and methods

Study population

This ambispective observational study was carried out at two Spanish University Hospitals. All patients with virological suppression at least for one year who switched to a dual therapy with either ATV<sub>rtv</sub> or ATV<sub>400</sub> plus 3TC once daily from January of 2011 to May of 2014 (retrospective part) and from June 2014 to December 2015 (prospective part) were included. The reasons for switching were the presence of adverse effects (AEs) with previous regimens, drug-drug interactions and simplification to a regimen with a lower pill burden. These regimens were not prescribed in case of pregnancy, hepatitis B coinfection or concomitant use of drugs with potential interactions with ATV pharmacokinetics. Additionally, the presence of cirrhosis with clinical or analytical data of liver failure, and ≥1 major resistance mutations to ATV (I50L, I84V, and N88S) or 3TC (K65R/E/N or M184I/V) in the genotypic resistance tests lead to exclusion of the patient. The study was designed and conducted according to the principles of the Declaration of Helsinki and was approved by the Spanish Agency of Medicines and Healthcare Products and the Coordinating Committee on Ethics in Biomedical Research of Andalucía. All patients provided signed informed consent, except in those retrospective cases as, according to Spanish law, the retrospective studies do not require informed consent if only completely anonymous information from existing records was collected, thereby ensuring the protection of personal data in accordance with the Personal Data Protection Organic Law 15/199 enacted on December 13, 1999.

Endpoints, follow-ups, and assessments

The primary clinical endpoint was treatment effectiveness, measured as the percentage of patients who maintained virological suppression after 48 weeks according to intention-to-treat analysis (non-complete/missing = failure). VF was defined as a confirmed plasma HIV-RNA of >200 copies/mL, considering the time of the first assessment meeting the failure criteria as the time of failure, or a single HIV-RNA level >200 copies/mL in case of subsequent loss of follow-up. A cut-off level of 200 copies/mL was chosen since it represents a more accurate measurement of VF than lower cut-off values [25,26]. The change of ATV<sub>rtv</sub> to ATV<sub>400</sub> due to intolerance to ritonavir was not considered as failure. Viral blip was defined as a single HIV-RNA value >50 copies/mL without subsequent confirmation. As a secondary outcome, virological efficacy and its relationship with plasma and intracellular ATV concentrations were assessed in an on-treatment approach where patients who were lost to follow-up, voluntarily dropped, discontinued therapy due to AEs or changed the study regimen due medical decision without VF criteria were excluded from analyses.

A standard checklist was used for recording information extracted from electronic medical records, including demographic variables, clinical and laboratory data at baseline, after 1 month, and every 3 months thereafter. CD4<sup>+</sup> T cell counts and plasma HIV-RNA were measured by flow cytometry and the Cobas AmpliPrep-Cobas TaqMan HIV-1 test (v 2.0, Roche Diagnostics, Basel, Switzerland; lower detection limit of 20 copies/mL), respectively. AEs were categorized via the standardized toxicity-grade scale used by the AIDS Clinical Trials Group [27]. However, in patients with chronic hepatitis C or cirrhosis, toxicity was classified according to changes relative to the baseline values rather than the upper limit of normality: grade 0, <1.25 x baseline; grade 1, (1.25 to 2.5) x baseline; grade 2, (2.6 to 3.5) x baseline; grade 3, (3.6 to 5) x baseline; and grade 4, >5 x baseline.

Pharmacokinetic data

A pharmacokinetic study was performed in the subgroup of patients included prospectively, where at least one sample per patient was obtained during the follow-up. Blood samples for
ATV C\text{\text{trough} were collected into EDTA and cell preparation tubes (CPTs; Becton Dickinson Vacutainer) at 24 ± 0.5 h after the previous dose taken after a standard breakfast (otherwise, blood samples were discarded). Within 1 h after collection, the tubes were centrifuged at 1500 g for 20 min at room temperature. Plasma was transferred to cryotubes and stored at -80°C until analysis. The cell layer from the CPT tubes was transferred to 15 mL Falcon tubes, peripheral blood mononuclear cells (PBMC) were then fast washed twice in 10 mL ice-cold 0.9% NaCl solution and centrifuged at 1500 g for 10 min at 4°C. The cell pellets were transferred to Eppendorf tubes and washed with 1.5 mL ice-cold 0.9% NaCl solution. Once centrifuged, the supernatants were aspirated and the cell pellets were weighed. Afterwards, the pellets were dissolved in 1ml extraction solution (methanol:water, 70:30, v/v), and then stored at -80°C, for no longer than 3 months, until analyses. For ATV intracellular concentrations, PBMC aliquots were weighed and their volume was calculated as volume = weight/density. Since the density of mononuclear cells is 1.077 and that of plasma 1.030, the weight of the aliquots was equalized with their volume.

Plasma and intracellular concentrations were determined by LC-MS/MS. The separation was performed on a Phenomenex Luna C18 (5 \mu m, 150 x 2.0 mm) analytical column. The mobile phase was composed of a 2 mM ammonium acetate 0.1% formic acid and acetonitrile 0.1% formic acid. The drugs were extracted from the blood plasma by protein precipitation, using acetonitrile containing a deuterated internal standard. The standard curves were highly linear over the range of 10 to 2000 ng/mL. The intra- and inter-assay precision and accuracy were <15% in both biological samples.

**Statistical analysis**

Categorical variables were compared using the \chi^2 test or the Fisher’s exact test, while quantitative variables were analyzed using the Student’s t test or the Mann–Whitney nonparametric test, respectively, according to their distribution. The ATV C\text{\text{trough} were summarized as geometric means (GM), interquartile range (IQR), and range. The intra- and inter-subject variability in ATV C\text{\text{trough} was assessed by the coefficients of variation (CV) of all the available values from each patient throughout the follow-up period. The correlations between plasma and intracellular concentrations were assessed by Spearman’s correlation coefficients. Time-to-event analyses were performed by using Kaplan–Meier survival curves and the log rank test. Variables with p-values < 0.2 in the univariate analysis, as well as those that potentially affect the efficacy of the treatments, such as age and gender, were entered into Cox proportional hazard models. The adjusted hazard ratio (AHR) and the respective 95% confidence intervals (CI) were calculated. Statistical analyses were performed using the IBM software (SPSS v. 23.0, Chicago, USA), and p-values <0.05 were considered significant.

**Results**

A total of 246 patients were included in the study, 149 on ATV\text{\text{rtv} and 97 on ATV\text{400, whose baseline characteristics are summarized in Table 1. Eighty-two and seventy-eight patients were included prospectively in the ATV\text{\text{rtv and ATV\text{400 group, respectively. Baseline characteristics of the patients according to the time of inclusion are provided in S1 Table.}}

The reasons for switching to dual therapy based on ATV were AEs with previous regimens (38.6%), drug-drug interactions (12.2%), and simplification (49.2%). Before switching to dual therapy, 69.5% of the patients were on an ATV\text{\text{rtv}-based regimen. Sixty-one patients (25%) had experienced a previous VF while on PI-based regimens (saquinavir, 36.1%; indinavir, 32.7%; nelfinavir, 16.4%; lopinavir, 11.5% and fosamprenavir, 3.3%), but no major resistance mutations for ATV were found in the genotype resistance tests just after these VFs. Eighty-eight
percent of these patients had a subsequent treatment based on ritonavir-boosted PI. During the follow-up, none of the patients changed from ATV<sub>rtv</sub> to ATV<sub>400</sub>.

### Effectiveness and safety

After a follow-up of 48 weeks, the Kaplan–Meier estimates of effectiveness by intention-to-treat analysis were 85.9% (CI<sub>95</sub>, 80.3–91.4%) and 87.6% (CI<sub>95</sub>, 81.0–94.1%), (p = 0.684) for ATV<sub>rtv</sub> and ATV<sub>400</sub> plus 3TC, respectively. The corresponding values obtained by on-treatment analyses were 97.7% (CI<sub>95</sub>, 95.2–100%) and 98.8% (CI<sub>95</sub>, 97.0–100%) (p = 0.546). When comparing the effectiveness in retrospectively and prospectively included patients, no differences were found (data not shown). Overall, three cases of VF occurred in the ATV<sub>rtv</sub> group (at month 3, 9 and 12) and only one case (at month 6) in the ATV<sub>400</sub> group; no results for genotype tests were available due to low HIV-RNA levels that impeded amplification. Two of these patients achieved virological suppression three months later; one of them by switching to a triple therapy regimen, and another one while continuing with the ATV dual therapy after adherence counseling. Treatment effectiveness was not affected by sex, presence of chronic

### Table 1. Baseline characteristics of the study populations.

|                          | ATV<sub>rtv</sub> + 3TC n = 149 | ATV<sub>400</sub> + 3TC n = 97 | p    |
|--------------------------|---------------------------------|--------------------------------|------|
| Male, no. (%)            | 113 (75.8)                      | 70 (72.2)                      | 0.521|
| Age, years, M (IQR)      | 49 (43–53)                      | 51 (45–56)                     | 0.026|
| Weight, kg, M (IQR)      | 70 (62–80)                      | 71 (65–81)                     | 0.633|
| Nadir CD4<sup>+</sup>/μl, M (IQR) | 166 (59–269)                  | 164 (90–268)                  | 0.354|
| Risk factor for HIV, no. (%) | 0.228                          |                                |      |
| Previous iv drug use     | 63 (42.3)                       | 39 (39.2)                      |      |
| Homosexual               | 46 (30.9)                       | 21 (21.6)                      |      |
| Heterosexual             | 40 (26.8)                       | 37 (38.1)                      |      |
| Chronic hepatitis C, no. (%) | 55 (36.9)                     | 43 (44.3)                      | 0.237|
| Cirrhosis no. (%)        | 18 (12.1)                       | 11 (11.3)                      | 0.832|
| Previous months on ART, M (IQR) | 91 (31–185)                  | 63 (33–118)                    | 0.004|
| Months with HIV-RNA < 20 copies/mL, M (IQR) | 60 (35–112)                  | 48 (24–80)                     | 0.333|
| Previous ART combinations |                                |                                | 0.182|
| PI<sub>rtv</sub> (+ 2 NRTIs), n (%) | 83 (55.7)                   | 63 (64.9)                      |      |
| Atazanavir               | 73 (88.0)                       | 61 (96.8)                      |      |
| Darunavir                | 3 (3.6)                         | 2 (3.2)                        |      |
| Lopinavir                | 7 (8.4)                         | 0 (0.0)                        |      |
| NNRTI (+ 2 NRTIs), n (%) | 16 (10.7)                       | 8 (8.2)                        |      |
| Efavirenz                | 6 (37.5)                        | 4 (50)                         |      |
| Nevirapine               | 1 (6.3)                         | 1 (12.5)                       |      |
| Rilpivirine              | 9 (56.3)                        | 3 (37.5)                       |      |
| INSTI (+ 2 NRTIs), n (%) | 6 (4.0)                         | 4 (4.1)                        |      |
| Elvitegravir             | 1 (16.7)                        | 1 (25.0)                       |      |
| Dolutegravir             | 0 (0.0)                         | 1 (25.0)                       |      |
| Raltegravir              | 5 (83.3)                        | 2 (50.0)                       |      |
| Other PI<sub>rtv</sub>, regimens, n (%) | 44 (29.7)                   | 22 (22.7)                      |      |
| CD4<sup>+</sup>/μl, M (IQR) | 693 (519–918)              | 698 (531–953)                  | 0.562|

M (IQR), Mean (interquartile range). ATV<sub>rtv</sub>, atazanavir boosted with ritonavir. ATV<sub>400</sub>, unboosted-atazanavir. ART, antiretroviral treatment. PI<sub>rtv</sub>, ritonavir-boosted protease inhibitor. NRTIs, nucleoside reverse transcriptase inhibitors. INSTI, integrase strand transfer inhibitor.

https://doi.org/10.1371/journal.pone.0203452.t001
hepatitis C, cirrhosis, previous ART, blips, previous VF or treatment group. In univariate analysis, only HIV risk factor was associated to high rate of treatment failure. This factor remained significant when a multivariate analysis was performed (Table 2).

In addition to VF, other treatment failures in the ATV_{rtv} group were due to AEs [grade 3 hyperbilirubinemia (n = 2; 1.3%)], loss to follow-up or voluntary treatment drop-out [n = 9 (6.0%)], and change of treatment to a single-tablet regimen due to medical decision without underlying VF criteria or AEs [n = 7 (4.7%)]. In the group of ATV_{400} the numbers of non-virological failures were 1 (1%) for AEs (grade 1 gastrointestinal disorder), 6 (6.2%) for loss to follow-up, and 4 (4.1%) for change of treatment by medical decision. All patients had an undetectable viral load at the time of the last available HIV-RNA assessment on ATV.

Table 2. Univariate and multivariate analyses to identify factors associated with treatment efficacy assessed in an intention-to-treat analysis (n = 246).

| Parameter                        | n   | Virological success, n (%) | p univariate | AHR (95% CI) | p multivariate |
|----------------------------------|-----|----------------------------|--------------|--------------|---------------|
| Age (years)                      |     |                            |              |              |               |
| < 50                             | 122 | 103 (84.4)                 | 0.324        | 0.96 (0.92–1.01) | 0.148         |
| ≥ 50                             | 124 | 110 (88.7)                 |              | 1            |               |
| BMI                              |     |                            |              |              |               |
| < 24                             | 91  | 81 (89)                    | 0.760        |              |               |
| ≥ 24                             | 138 | 121 (87.7)                 |              |              |               |
| Gender                           |     |                            |              |              |               |
| Female                           | 63  | 54 (84.1)                  | 0.507        | 0.57 (0.26–1.25) | 0.163         |
| Male                             | 183 | 160 (87.4)                 |              |              |               |
| Previous iv drug use             |     |                            |              |              |               |
| No                               | 145 | 133 (91.7)                 | 0.005        | 3.73 (1.50–9.28) | 0.005         |
| Yes                              | 101 | 80 (79.2)                  |              |              |               |
| Chronic hepatitis C              |     |                            |              |              |               |
| No                               | 146 | 130 (89)                   | 0.153        | 1.18 (0.51–2.73) | 0.697         |
| Yes                              | 98  | 81 (82.7)                  |              |              |               |
| Cirrhosis                        |     |                            |              |              |               |
| No                               | 210 | 182 (86.7)                 | 0.653        |              |               |
| Yes                              | 29  | 26 (89.7)                  |              |              |               |
| Previous ART                     |     |                            |              |              |               |
| PI-based                         | 221 | 207 (98.1)                 | 0.831        |              |               |
| NNRTI-based                      | 24  | 24 (100)                   |              |              |               |
| INSTI-based                      | 10  | 10 (100)                   |              |              |               |
| Previous VF with PI              |     |                            |              |              |               |
| No                               | 184 | 160 (87)                   | 0.989        |              |               |
| Yes                              | 61  | 53 (86.9)                  |              |              |               |
| Previous blips                   |     |                            |              |              |               |
| No                               | 198 | 173 (87.4)                 | 0.678        |              |               |
| Yes                              | 47  | 40 (85.1)                  |              |              |               |
| Treatment group                  |     |                            |              |              |               |
| ATV_{rtv}                        | 149 | 128 (85.9)                 | 0.698        |              |               |
| ATV_{400}                        | 97  | 85 (87.6)                  |              |              |               |

AHR: adjusted hazard ratio; CI: confidence interval; VF: virological failure; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; INSTAT, integrase strand transfer inhibitor; ATV_{rtv}, ritonavir-boosted atazanavir; ATV_{400}, unboosted atazanavir

*entered as continuous variable in the multivariate analysis; Virological success: proportion of patients with plasma HIV-RNA < 20 copies/mL at 48 weeks.

https://doi.org/10.1371/journal.pone.0203452.t002
During the 48 weeks of follow-up, 20 (13.4%) patients on ATV \textsubscript{rtv} experienced blip episodes (1 blip, 17 patients; 2 blips, 3 patients), while only eight (8.2%) patients on ATV \textsubscript{400} experienced nine blip episodes (p = 0.148), with a median HIV-RNA of 129 copies/mL (IQR, 79–273).

The median increase in CD4\textsuperscript{+} T cell counts from baseline to week 48 was 20 cells/\mu L (IQR, -80–124) and 50 cells/\mu L (IQR, -85–133) in the ATV\textsubscript{rtv} and ATV\textsubscript{400} groups, respectively, being inversely proportional to the baseline CD4\textsuperscript{+} T cell counts (r = -0.248 and -0.375, respectively; p = 0.006).

Aminotransferase level elevations throughout the follow-up period occurred in 4 patients in the ATV\textsubscript{rtv} group (grade 1, 2; grade 2, 2), three of them suffered chronic hepatitis C, and in 1 patient in the ATV\textsubscript{400} group (grade 1), who was also coinfected by hepatitis C virus. These alterations were transient and improved without treatment modification in all cases. Regarding changes in lipid profiles between baseline and week 48, no significant differences between the ATV\textsubscript{rtv} and ATV\textsubscript{400} groups were observed, with median changes (mg/dL) of 8 (IQR, -10–28) versus -12 (IQR, -39–22) in fasting total cholesterol, 1 (IQR, -7–7) versus -2 (IQR, -11–1) in HDL-cholesterol, 12 (IQR, -10–34) versus -12 (IQR, -27–9) in LDL-cholesterol, and 4 (IQR, -45–52) versus -25 (IQR, -62–-1) in triglycerides, respectively.

**Pharmacokinetics of ATV**

The pharmacokinetics study was conducted in a sub-group of 63 and 78 patients in the ATV\textsubscript{rtv} and ATV\textsubscript{400} group, respectively. ATV C\textsubscript{trough} were determined in 339 plasma samples (ATV\textsubscript{rtv}, 108; ATV\textsubscript{400}, 231), and in 35 PBMCs samples of each group (Fig 1). In both plasma and intracellular compartments, the ATV C\textsubscript{trough} were higher with ATV\textsubscript{rtv} than with ATV\textsubscript{400}. In plasma samples, the ATV concentrations ranged from 49.6 to 3698.0 ng/mL with a GM of 605.9 ng/mL (IQR, 370.4–1063.3) for ATV\textsubscript{rtv} and from 45.1 to 1755.0 ng/mL (GM, 318.3 ng/mL; IQR, 218.5–483.4) for ATV\textsubscript{400} (p < 0.001). Whereas in PBMCs samples, the corresponding values were 2659.2 (IQR, 1213.3–5940.7; range 163.7–10743.0) vs. 811.3 ng/mL (IQR497.5–1180.4; range 235.8–8778.6) (p < 0.001) for ATV\textsubscript{rtv} and ATV\textsubscript{400}, respectively. Likewise, the mean intracellular penetration, evaluated as intracellular/plasma C\textsubscript{trough} ratios was higher in the ATV\textsubscript{rtv} group than in the ATV\textsubscript{400} group (4.39 vs. 2.54; p < 0.001). There was a correlation between the plasma and intracellular C\textsubscript{trough} in patients taking ritonavir-boosted ATV (r = 0.754, p < 0.001), but not in those on unboosted ATV (r = 0.252, p = 0.123).

ATV concentrations below the suggested minimum effective concentration of 150 ng/mL were detected in two (1.8%) samples from 2 patients of the ATV\textsubscript{rtv} group and 43 (17.7%) samples from 12 patients of the ATV\textsubscript{400} group. Given the low number of VF, it was not possible to establish any relationship between VF and plasma or intracellular concentrations, however, none of the patients with plasma ATV C\textsubscript{trough} below 150 ng/mL had VF. No association between blip episodes and a low ATV C\textsubscript{trough} was observed. Likewise, there were no relationships.

![Fig 1](https://doi.org/10.1371/journal.pone.0203452.g001)
between plasma and intracellular ATV concentrations and weight or body mass index, and there were no differences in plasma and intracellular ATV concentrations with respect to gender or the presence of cirrhosis.

For the ATV<sub>rtv</sub> and ATV<sub>400</sub> groups, the median intra-subject variability for ATV was 32.3% and 44.6% in plasma samples and 34.5% and 40.3% for intracellular ATV. The corresponding median inter-subject variability was 197.23% and 99.23% in plasma, and 118.8% and 97.2% for cellular samples.

**Discussion**

In the last years, several ART simplification strategies have been studied in order to reduce the severity or even avoid AEs from chronic drug exposure, lower the risk of HIV-1 drug resistance, and achieve more cost-effective regimens. Among them are dual therapies based on ritonavir-boosted PIs in combination with 3TC or other drugs that have shown good efficacy rates and safety profiles, being this simplified regimen an option in low resource settings or when clinicians prefer the least number of drugs possible for their patients. [11–13, 28–30]. ATV is the only HIV-1 protease inhibitor currently in use that can be administered without a pharmacokinetic enhancer, although a dose increase from 300 to 400 mg daily is recommended for the unboosted regimen. Apart from the prevention of potential drug-drug interactions, this adaptability enables to manage both ritonavir-induced toxicity and hyperbilirubinemia caused by high ATV concentrations.

In spite of being a study performed in the routine clinical practice, a high effectiveness of ATV plus 3TC was observed at 48 weeks, although it should be taken into account that most of patients of the study were virologically suppressed for a long time. Furthermore, less than 2% of the population presented AEs that led to treatment discontinuation, which may partly be explained by the large proportion of patients who were already on an ATV<sub>rtv</sub>-based regimen before switching to dual therapy. Our results are similar to those reported by the ATLAS-M clinical trials [12], where the efficacy rates at week 48 by intention-to-treat and on-treatment analyses were 89.5% (CI<sub>95</sub>, 84.3–94.7%) and 90.1% (CI<sub>95</sub>, 85.0–95.2%) respectively, and even better than those in the SALT trial [13] that found an efficacy rates of 78% and 83%. Both trials demonstrated the non-inferiority of this combination compared to ATV<sub>rtv</sub> + 2 plus two NRTIs in long-term supressed patients. To our knowledge, only two studies of dual therapy comprising ATV<sub>400</sub> plus 3TC [19–20] are available. In one, patients with virological suppression on ATV<sub>400</sub> plus two NRTIs were switched to ATV<sub>400</sub> plus 3TC or emtricitabine, without any VF or discontinuation after 48 weeks. In the other study, treatment-experienced HIV-infected patients were switched from triple therapy to boosted or unboosted ATV plus 3TC with no VF. However, the latter study only analyzed the first six months after switching to dual therapy, and sample sizes were as low as 40 and 20 patients, respectively.

In accordance with previous pharmacokinetic studies, the herein presented work finds lower ATV C<sub>trough</sub> in the non-boosted regimen as compared with the ritonavir-boosted regimen both in plasma and on intracellular level [31–33]. The underlying mechanism is likely the potent inhibitory effect of ritonavir on P-glycoprotein, of which atazanavir is substrate, thus facilitating a better absorption and the accumulation of the drug on the intracellular level [34–35]. In the ATV expanded access program, Gonzalez de Requena et al. [21] found that an ATV C<sub>trough</sub> lower than 150 ng/mL was associated with a high probability of VF in PI-experienced patients, most of them showing plasma HIV-RNA loads higher than 1000 copies/mL. In contrast, none of the patients with a plasma ATV C<sub>trough</sub> below 150 ng/mL had VF in the present study, although it is to note that the clinical condition of the herein analyzed populations was different regarding their virological and immunologic status.
One of the limitations of this study is that in the last years the use of ATV<sub>rtv</sub> is progressively decreasing since it is being replaced by a co-formulation including the pharmacokinetic enhancer cobicistat, which is not analyzed in the present study. However, two randomized, crossover bioequivalence studies have shown that ATV/cobicistat (300/150 mg) provides bioequivalent ATV exposures as compared to ATV<sub>rtv</sub>, both in healthy volunteers and treatment-naïve adults infected with HIV-1 [36–37]. Although cobicistat shows a better tolerance and drug-drug interaction profile than ritonavir, in some settings it should be avoided and ATV<sub>400</sub> may be a good alternative. Another limitation is the low number of blood samples for pharmacokinetics study, since this substudy was only conducted in the prospective part. However, the determination of ATV plasma levels was not the primary aim of the study and furthermore, still a considerable number of samples were obtained.

In conclusion, our data suggest that boosted or unboosted atazanavir plus lamivudine represent comparable simplification strategies regarding effectiveness and safety in HIV-infected patients with long-term virological suppression. Although lower plasma and intracellular ATV C<sub>trough</sub> is observed with ATV<sub>400</sub>, this does not appear to compromise the effectiveness of these regimens in virologically suppressed patients. However, the lasting efficacy of this regimen would need further investigation with clinical trials.

Supporting information

S1 Table. Baseline characteristic according to period of inclusion and treatment group. M (IQR), Mean (interquartile range). ATV<sub>rtv</sub>, atazanavir boosted with ritonavir. ATV<sub>400</sub>, unboosted-atazanavir. ART, antiretroviral treatment. PI<sub>rtv</sub>, ritonavir-boosted protease inhibitor. NRTIs, nucleoside reverse transcriptase inhibitors. INSTI, integrase strand transfer inhibitor. (DOCX)

Acknowledgments

The authors are indebted to the patients for their involvement in this study.

Author Contributions

Conceptualization: Alicia Gutierrez-Valencia, Juan Pasquau, Luis Fernando López-Cortés.

Data curation: Alicia Gutierrez-Valencia, Luis Fernando López-Cortés.

Formal analysis: Alicia Gutierrez-Valencia, Luis Fernando López-Cortés.

Funding acquisition: Alicia Gutierrez-Valencia, Luis Fernando López-Cortés.

Investigation: Alicia Gutierrez-Valencia, Coral García, Pompeyo Viciana, Yusnelkis Milanés-Guisado, Tamara Fernandez-Magdaleno, Juan Pasquau, Luis Fernando López-Cortés.

Methodology: Alicia Gutierrez-Valencia, Juan Pasquau, Luis Fernando López-Cortés.

Resources: Nuria Espinosa.

Supervision: Alicia Gutierrez-Valencia, Luis Fernando López-Cortés.

Writing – original draft: Alicia Gutierrez-Valencia.

Writing – review & editing: Luis Fernando López-Cortés.
References

1. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med. 1998; 339:1261–1268. https://doi.org/10.1056/NEJM199810293391981 PMID: 9791141

2. Pialoux G, Raffi F, Brun-Vezinet F, Meltrud S, Flandre P, Gastaud JA, et al. Randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N Engl J Med 1998; 339: 1269–1276. https://doi.org/10.1056/NEJM199810293391982 PMID: 9791142

3. Arribas JR, Doroana M, Turner D, Vanderkerckhove L, Stienau-Ceruel A. Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. AIDS Res Ther. 2013; 10:3. https://doi.org/10.1186/1742-6405-10-3 PMID: 23347959

4. Lopez-Cortes LF, Castano MA, Lopez-Ruz MA, Rios-Villegas MJ, Hernandez-Quero J, Merino D et al. Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens. PLoS One 2016; 11: e0148924. https://doi.org/10.1371/journal.pone.0148924 PMID: 26872331

5. Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014; 14:572–80. https://doi.org/10.1016/S1473-3099(14)70736-4 PMID: 24783988

6. Maggio F, Di Filippo E, Valenti D, Ortega PS, Callegaro A. NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe). J Acquir Immune Defic Syndr. 2016; 72:46–51. https://doi.org/10.1097/QAI.0000000000000966 PMID: 26910503

7. Casado JL, Banon S, Rodriguez MA, Perez-Elias MJ, Moreno A, Moreno S. Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity. J Antimicrob Chemother 2015; 70: 630–2. https://doi.org/10.1093/jac/dku402 PMID: 25304644

8. Mondi A, Fabbiani M, Ciccarelli N, Ciafaglì M, D’Avino A, Borghetti A et al. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the ATLAS pilot study. J Antimicrob Chemother 2015; 70: 1843–9. https://doi.org/10.1093/jac/dkv037 PMID: 25885326

9. Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D’Ettorre G, Antinori A et al. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017; 72:1163–1171. https://doi.org/10.1093/jac/dkw557 PMID: 28093483

10. Perez-Molina JA, Rubio R, Rivero A, Pascual J, Suarez-Lozano I, Riera M et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2015; 15:775–84. https://doi.org/10.1016/S1473-3099(15)00097-3 PMID: 26062881

11. Móbius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt E et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr. 2005; 39: 37–40. PMID: 15905733

12. Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Ciotet B, Ribera E et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr. 2009; 51: 29–36. https://doi.org/10.1097/QAI.0b013e3181f2a26f PMID: 19390327

13. Gatell J, Salmon-Ceron D, Lazarin A, Van Wijngaerden E, Antunes F, Leen C et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virological suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007; 44: 1484–92. https://doi.org/10.1086/517497 PMID: 17479947

14. Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, Gonzalez-García J, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr. 2009; 51:153–62. https://doi.org/10.1097/QAI.0b013e3181a5701c PMID: 19346966

15. Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010; 24:2019–27. https://doi.org/10.1097/QAD.0b013e32833bee1b PMID: 20613461
Molto J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, et al. Monitoring atazanavir concentrations.

16. Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, et al. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther. 2010; 15:993–1002. https://doi.org/10.3851/IP1666 PMID: 21041914

17. Ferraris L, Viganò O, Peri A, Tarkowski M, Milani G, Bonora S, et al. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. J Antimicrob Chemother. 2012; 67:2236–42. https://doi.org/10.1093/jac/dks175 PMID: 22661571

18. Llibre JM, Cozzi-Lepri A, La Rosa JA, Pedersen C, Ristola M, Losso M, et al. Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. J Int AIDS Soc. 2014; 17(4 Suppl 3):19810.

19. Carbone A, Galli L, Bigoloni A, Bossolasco S, Guffanti M, Maillard M, et al. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. Int AIDS Soc. 2014; 17(4 Suppl 3):19811.

20. Rigo F, Cucchietti G, Lanzafame M, Nicolè S, Lattuada E, Concina E, et al. Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients. HIV Med. 2017; 18:790–792. https://doi.org/10.1111/hiv.12523 PMID: 28503915

21. Gonzalez de Requena D, Bonora S, Canta F, Marrone R, D’Avolio A, Sciandra M et al. Atazanavir trough is associated with efficacy and safety: definition of therapeutic range. In: Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 646. 6th International Workshop on Clinical Pharmacology of HIV therapy, Quebec, 2005.

22. Regazzi M, Villani P, Guiminetti R, Usato M, Brandolini M, Tinelli C, et al. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Ther Drug Monit. 2011; 33:303–8. https://doi.org/10.1097/FTD.0b013e31821c2772 PMID: 21544015

23. Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, et al. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve. Pharmacotherapy. 2013; 33:284–94. https://doi.org/10.1002/phar.1205 PMID: 23456732

24. Bonora S, Gonzalez de Requena D, D’Avolio A, Calcagno A, Tettoni M, Siccardi M, et al. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. Antivir Ther. 2011; 16:499–504. https://doi.org/10.1080/20420970.2010.514514 PMID: 21685537

25. Ruelle J, Debaissieux L, Vancutsem E, De Bel A, Delforge ML, Piéard D, et al. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect Dis. 2012; 12: 100. https://doi.org/10.1186/1471-2334-12-100 PMID: 22530816

26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2016. Available from: http://aidsinfo.nih.gov/guidelines/. Accessed on 5/2/2016.

27. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. [November 2014]. Available from: http://rsc-tech-res.com/docs/defaultsafety/saids_ae_grading_table_v2_nov2014.pdf

28. Calza L, Caflaggi M, Colangelo V, Borderi M, Barchi E, Lanzafame M et al. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Lond). 2017:1–9

29. Pulido F, Ribera E, Lagarte M, Pérez-Valero I, Palacios R4, Iribaren JA et al. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine for Abacavir and Lamivudine for Maintenance of Human Immuno deficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014- RIS-EST45 Trial. Clin Infect Dis. 2017; 65:2112–2118 https://doi.org/10.1093/cid/cix734 PMID: 29020293

30. Latini A, Fabbiani M, Borghi V, Serrantinio G, Giannetti A, Lorenzini P et al. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis. 2016; 16: 401. https://doi.org/10.1186/s12879-016-1703-z PMID: 27515949

31. Motoj J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit. 2007; 29:648–51. https://doi.org/10.1097/FTD.0b013e31815704c1 PMID: 17899658
32. Colombo S, Buclin T, Cavassini M, Décoisard LA, Telenti A, Biollaz J et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006; 50:3801–8. https://doi.org/10.1128/AAC.00098-06 PMID: 16940065

33. Smith DE, Jeganathan S, Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006; 7:34–8. https://doi.org/10.1310/0KX0-H9VH-99EE-5D0L PMID: 16632461

34. Khoo SH, Hoggard PG, Williams I, Meaden ER, Wilkins EG, et al. Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother. 2002; 46:3228–35. https://doi.org/10.1128/AAC.46.10.3228-3235.2002 PMID: 12234849

35. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014; 69:3061–6. https://doi.org/10.1093/jac/dku234 PMID: 24997317

36. Ramanathan S, Warren D, Wei L, Kearney BP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS-9350 versus ritonavir. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, USA; September 12–15, 2009.

37. Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011; 25(15):1881–6 https://doi.org/10.1097/QAD.0b013e32834b4d48 PMID: 21811136